|
|
|
| Clinical Study of Nedaplatin Combined with Recombinant Human Vascular Endostatin Hyperthermia Chemotherapy On the Treatment of Cancerous Ascites |
| HUANG Han-sheng, FU Jun-min, WEN Jian-mei, et al |
| The Second Affiliated Hospital of Guangxi University of Science and Technology,Guangxi Liuzhou, 545006 |
|
|
|
|
Abstract 【Objective】To analyze the clinical application of nedaplatin combined with recombinant human vascular endostatin hyperthermia chemotherapy in the treatment of cancerous ascites. 【Methods】The clinical data of 60 patients with cancerous ascites admitted to our hospital from December 2015 to December 2018 were analyzed. They were divided into two groups with 30 cases each: the control group was treated with nedaplatin hyperthermia chemotherapy and the observation group was treated with nedaplatin combined with recombinant human vascular endostatin hyperthermia chemotherapy. The clinical efficacy of the two groups was analyzed before and after treatment. 【Results】In the observation group, there were 14 cases of complete remission and 13 cases of partial remission. Its total effective rate was 90.00%. In the control group, there were 6 cases of complete remission and 14 cases of partial remission. So, the total effective rate was 66.67%. The difference was statistically significant (χ2=4.812, P=0.028<0.05).There were no significant differences between the two groups in the levels of tumor markers CEA, glycoprotein antigen 19-9 (CA19-9) ,vascular endothelial growth factor (VEGF) and tumor necrosis factor alpha (TNF-α) before treatment (P>0.05). The levels of CEA, CA19-9,VEGF and TNF-α in the observation group were lower than those in the control group (P<0.05).The quality of life (Karnofsky score) in the observation group was 96.67% (29/30), which was significantly higher than that of the control group 73.33% (22/30). The difference was statistically significant (χ2=6.405,P=0.011<0.05). The adverse reactions of the two groups were all in grade Ⅰ~Ⅱ, and the occurrence of adverse reactions in the two groups was not statistically significant (P>0.05). 【Conclusion】Nedaplatin combined with recombinant human vascular endostatin thermal perfusion for the treatment of cancerous ascites has better clinical efficacy, which can reduce the levels of tumor markers, improve patients' quality of life without increasing adverse reactions.
|
|
Received: 11 March 2019
|
|
|
|
|
|
[1] 吴印兵,潘明新,崔书中,等.B超引导下持续循环腹腔热灌注化疗治疗恶性腹水的临床应用初探[J].实用医学杂志,2016,32(3):440-443.
[2] 苏永超,吴挺洲,李妮,等.榄香烯脂质体联合奈达铂腔内灌注治疗小细胞肺癌恶性胸腔积液的效果[J].广东医学,2017,38(z1):232-233.
[3] 陈国宁,蔡茂怀.紫杉醇、奥沙利铂联合榄香烯腹腔灌注治疗胃癌晚期癌性腹水的临床观察[J].中国药房,2016,27(36):5095-5097.
[4] 宾业鸿,郑海平,蓝东,等.SOX联合多西他赛腹腔灌注与DOS方案一线治疗晚期胃癌伴癌性腹水的对比研究[J].中华肿瘤防治杂志,2016,23(16):1085-1089.
[5] 沈文拥,吴涛,唐静,等.腹腔镜和经胃的自然腔道内镜手术在不明原因腹水诊断中的临床应用比较[J].中国内镜杂志,2017,23(1):56-60.
[6] Igawa S,Otani S,Nakahara Y,et al.Phase I study of Nedaplatin,a platinum based antineoplastic drug,combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer[J].Invest New Drugs,2017,36(2):1-8.
[7] 王贲士,柴杰,单军奇,等.多西他赛联合奈达铂新辅助治疗同期双原发胃癌肺癌并获得胃癌临床病理完全缓解一例[J].中华胃肠外科杂志,2017,20(5):589.
[8] 周毅,周健,张莹,等.培美曲塞联合奈达铂治疗晚期肺腺癌临床疗效及其安全性观察[J].第三军医大学学报,2018,40(13):1236-1241.
[9] 王昕雯.奈达铂或顺铂分别联合紫杉醇同步放疗用于中晚期宫颈癌的疗效比较[J].中国药房,2017,28(3):318-320.
[10] 付文娟,常娜,王帅,等.奈达铂腔内灌注治疗恶性胸腹水疗效观察[J].海南医学,2016,27(21):3482-3484. |
|
|
|
2019, Vol. 36 
